ResearchBib Share Your Research, Maximize Your Social Impacts
Sign for Notice Everyday Sign up >> Login

Possibilities of immunogistochemical investigation in respons prognosis to treatment and modification of treatment activities at luminal breast cancer (literature review)

Journal: Medicni perspektivi (Vol.22, No. 4)

Publication Date:

Authors : ;

Page : 4-12

Keywords : breast cancer; immunohistochemical investigation; hormonal therapy;

Source : Downloadexternal Find it from : Google Scholarexternal


This article is concerned with both standard (estrogen and progesterone receptors, Her2/neu and Ki67) immu­nohistochemical investigation in hormonal therapy tactics decision for luminal breast cancer and additional in­vestigation of such hormonal sensibility marker as cyclin D1, Bcl-2, AIB1, Her1, p53, IGF-IR, COX-2 and its influence on modified hormonal therapy impact on tumor. It was shown that tumors expressing Her2/neu, AIB1, Her1, p53 or tumors, that have more than 30% expression of cyclin D1 are resistant to antiestrogen but sensible to aromatase inhibitors. IGF-IR and COX-2 tumors are resistant to aromatase inhibitors. Metformin usage for IGF-IR hyperexpression and oxygenase selective inhibitors for COX-2 expression promotes sensibility increase for aromatase inhibitors.

Last modified: 2017-12-20 21:16:36